Background: Despite improvement in the management modalities of serous ovarian carcinoma (SOC) which is the commonest subtype of malignant epithelial ovarian tumors it still has a dismal prognosis due to its late diagnosis at advanced stages and resistance to chemotherapy. So discovering novel therapeutic targets will be beneficial to improve its prognosis. Spalt-like transcription factor 4 (SALL4) is the zinc finger transcriptional factor which controls several genes that are involved in normal development, in maintaining embryonic stem cells pluri-potency and selfrenewal. Beclin-1 (BECN1), which is considered the human counterpart of yeast Atg6/Vps30, is mapped to the tumor susceptibility locus 150 kb beside BRCA1 gene on chromosome 17q21. The detailed clinicopathological role of SALL-4 & BECN1 in SOC is not well clarified yet. Aim of the study: To assess the clinicopathological significance of SALL-4& BECN1 protein expression in Serous Ovarian Carcinoma tissues, by comparing their expression with standard clincopathological prognostic parameters as tumor grade, stage, presence of lymph node and distant metastases. Methods: Immunohistochemical expression of SALL-4& BECN1 was evaluated in sections from 60 archival paraffin blocks of serous ovarian carcinoma. The relationship between their tissue protein expression levels and clinicopathological criteria of such type of cancer was evaluated. Results: SALL-4 high expression and BECN1 low expression in SOC was associated worse clincopathological criteria e.g. higher grade (p=0.002) & advanced stage of the tumor, L.N metastases (p=0.004), peritoneal implants (p=0.006), presence of distant metastases (p<0.001), bilaterality (p=0.03) and ascites (p=.005). Conclusion: SALL4 overexpression in addition to BECN-1 lower expression is markers of poor prognosis in SOC.